2seventy bio, Inc. (NASDAQ:TSVT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of 2seventy bio, Inc. (NASDAQ:TSVT) have been assigned an average rating of “Moderate Buy” from the six research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $7.20.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of 2seventy bio in a research report on Wednesday.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TSVT. Bank of America Corp DE boosted its holdings in shares of 2seventy bio by 317.1% in the fourth quarter. Bank of America Corp DE now owns 2,515,897 shares of the company’s stock valued at $7,397,000 after acquiring an additional 1,912,771 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new stake in 2seventy bio during the fourth quarter valued at approximately $3,689,000. Toronto Dominion Bank acquired a new stake in 2seventy bio during the fourth quarter valued at approximately $2,352,000. Western Standard LLC lifted its stake in 2seventy bio by 175.7% during the fourth quarter. Western Standard LLC now owns 788,350 shares of the company’s stock valued at $2,318,000 after purchasing an additional 502,419 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new stake in 2seventy bio during the fourth quarter valued at approximately $913,000. 93.90% of the stock is currently owned by institutional investors.

2seventy bio Trading Up 7.5 %

NASDAQ TSVT opened at $2.57 on Thursday. 2seventy bio has a 52 week low of $2.29 and a 52 week high of $6.40. The stock has a market cap of $132.59 million, a price-to-earnings ratio of -1.38 and a beta of 1.74. The company has a 50-day moving average price of $2.72 and a two-hundred day moving average price of $3.85.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.